Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Parkinson’s Disease Psychosis | Unmet Need | US/FR/DE/UK | 2020

Login to access report north_east
Contact sales account_box

Parkinson’s disease (PD) is widely recognized as a motor disorder, but PD is also associated with a diverse set of nonmotor symptoms. Surveyed neurologists estimate that 20% of their PD patients experience psychosis, and DRG Epidemiology data suggest the percentage could be even higher. Few antipsychotic agents have been rigorously tested in the PD population, but prescribing of these agents is common; left untreated, psychosis can have a devastating effect on PD patients’ quality of life. One antipsychotic agent is approved for PD psychosis in the United States (Nuplazid) and one in Europe (clozapine), but clear unmet need remains. Understanding prescriber perceptions of the available on- and off-label options and the drivers of clinical decision-making in PD psychosis will help developers of antipsychotics and other agents gauge the market opportunity in PD and identify levers for new product positioning and differentiation in this underserved therapy market.

QUESTIONS ANSWERED

  • What drug attributes are most influential in prescribing for psychosis in the PD population? How do Nuplazid, clozapine, and commonly prescribed off-label agents perform on these attributes?
  • What are the specific areas of unmet need and opportunity in the treatment of PD psychosis?
  • Based on conjoint analysis and TPP simulation, what trade-offs between efficacy, safety, and price are neurologists willing to make for a hypothetical new antipsychotic agent for PD psychosis?

PRODUCT DESCRIPTION

Unmet Need provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 30 European neurologists, fielded in February 2020

Key drugs: Nuplazid (pimavanserin), clozapine, quetiapine, aripiprazole, olanzapine, risperidone, ziprasidone

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)
First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…
north_east
Report
Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)
Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While…
north_east
Report
Eosinophilic Esophagitis – Unmet Need – Unmet Need – Eosinophilic Esophagitis (US/EU)
Standard treatments for eosinophilic esophagitis (EoE) typically include proton pump inhibitors (PPIs) and swallowed topical steroids. Although these therapies can alleviate EoE symptoms, their…
north_east
Report
Breast Cancer – Geographic Focus: China – China In-Depth – Breast Cancer
China’s breast cancer market continues to evolve rapidly, driven by rising incidence and expanding systemic treatment options. Several new and emerging therapies are expected to gain approval for…
north_east
Report
Chronic Obstructive Pulmonary Disease – Unmet Need – Unmet Need – Severe to Very Severe Chronic Obstructive Pulmonary Disease (US EU)
The severe to very severe chronic COPD market is crowded, with numerous LAMA, LABA/ICS, LABA/LAMA, and triple LABA/LAMA/ICS inhalers competing for use. Although dual and triple longacting…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east